G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates. Source
No articles found.
Esperion is a pharmaceutical company passionately committed to developing and comm...
Esperion is a pharmaceutical company passionate...
KemPharmÂŽ is a clinical-stage specialty pharmaceutical company engaged in the dis...
KemPharmÂŽ is a clinical-stage specialty pharma...
Natural Health Trends Corporation (NASDAQ: NHTC) is an international direct-sellin...
Natural Health Trends Corporation (NASDAQ: NHTC...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
Join the National Investor Network and get the latest information with your interests in mind.